Highly potent active pharmaceutical ingredients (HPAPIs) represent an increasing fraction of new compounds in pharmaceutical pipelines today. Flexible and phase-appropriate infrastructure is needed to bring the next innovative medicines based on these challenging compounds from concept to commercialization. This webinar describes Lonza's HPAPI "manufacturing 4.0" investments and the company's innovative capabilities. Case studies are presented, demonstrating a range of solutions for HPAPI manufacturing, integrated drug substance and drug product development, and innovative business models.
To learn more, download the webinar slides.